GWGuo-Xiang Wang

Guo-Xiang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guo-Xiang Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Chun-Jiu Hu

    Department of Gastroenterology, Ningbo First Hospital, Ningbo 315000, Zhejiang Province, China

    1 shared publication
  • Di Wang

    Department of Laboratory Medicine, Huashan Hospital North, Shanghai Medical College, Fudan University, Shanghai 201907, China

    1 shared publication
  • Guojun Cao

    Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China; Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China

    1 shared publication
  • Sheng Tan

    Department of Cardio-Thoracic Surgery, Xuzhou Medical College Affiliated Hospital, Xuzhou, China

    1 shared publication
  • Xing

    Department of Laboratory Medicine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.

    1 shared publication
  • Yongbo Hou

    Department of Cardio-Thoracic Surgery, Xuzhou Medical College Affiliated Hospital, Xuzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Direct interaction between Rab5a and Rab4a enhanced epidermal growth factor-stimulated proliferation of gastric cancer cells

    by Guo-Jun Cao, Di Wang, Zhao-Pei Zeng, Guo-Xiang Wang, Chun-Jiu Hu, Zhi-Fang Xing

    Gastric cancer (GC) is one of the leading causes of cancer-related death world wide. Although targeted therapies such as antibodies against human epidermal growth factor receptor 2 or vascular endothelial growth factor receptor 2 have been widely used in the treatment of metastatic cancer, the overall outcomes are poor. Therefore, elucidation of the mechanism underlying cancer progression is important to improve prognosis. Overexpression of the Rab5a gene has been confirmed to correlate with tumorigenesis of many cancers, but the mechanism underling, especially of GC, is still unclear. To investigate the effects of Rab5a overexpression on the tumorigenesis of GC. First, the expression levels of Rab5a and Rab4a in primary tumorous tissues of GC patients diagnosed between 2015 and 2018 were analyzed. Then we constructed HGC-27 cell lines overexpressing green fluorescent protein-Rab5a or red fluorescent protein-Rab4a and investigated the interaction between Rab5a or Rab4a using Western blotting, co-immunoprecipitation, confocal microscopy, and colocalization analysis. Finally, epidermal growth factor-stimulated proliferation of these cell lines was analyzed using cell counting kit-8 cell viability assay. Compared with normal gastric tissues, the expression levels of Rab5a and Rab4a increased progressively both in paracancerous tissues and in advanced cancerous tissues. Epidermal growth factor could promote the proliferation of HGC-27 cells, especially Rab5a-overexpressing HGC-27 cells. Notably, Rab5a and Rab4a co-overexpression promoted the proliferation of HGC-27 cells to the greatest extent. Further analysis identified a direct interaction between Rab5a and Rab4a in HGC-27 cells. Co-overexpression of Rab5a and Rab4a in GC may promote the endosomal recycling of epidermal growth factor receptor, which in turn contributes to poor prognosis and tumor progression in GC patients. Inhibition of Rab5a or Rab4a expression might be a promising therapy for refractory GC.


  • Significance of TP53 Mutation in Cellular Process and Disease Progression in Lung Adenocarcinoma

    by Yongbo Hou, Sheng Tan, Guoxiang Wang

    Introduction: TP53 (tumor protein p53) is one of the most commonly mutanted genes in lung adenocarcinoma (LUAD). Materials and Methods: In this study, we used data from The Cancer Genome Atlas (TCGA) to evaluate the importance of TP53 mutations in cellular processes, disease progression, the prognosis in LUAD, and to identify critical hub genes and pathways associated with oncogenesis. Results: Analysis of the TCGA data showed TP53 mutations in 22% of LUAD patients. Clinicopathological analyses demonstrated that TP53 mutation was correlated with the disease progression but not prognosis. We identified 1935 differentially expressed genes (DEGs). Functional enrichment analysis showed that the DEGs were mainly concentrated in metabolism, cell differentiation, and cancer-related pathways. The top hub genes were identified and disease analysis revealed the most critical genes related to disease progression and prognosis. The expression levels of several of these genes were then tested in tumor tissues. Conclusion: Our results showed that TP53 mutation plays a critical role in cellular process and the clinicopathological findings in LUAD. We also identified potential key genes, which could provide novel evidence for individualized treatment.